Your browser doesn't support javascript.
loading
A study of the efficacy and safety of using hepatitis B surface antigen-positive donors for liver transplantation / 中华肝脏病杂志
Chinese Journal of Hepatology ; (12): 14-16, 2012.
Article in Chinese | WPRIM | ID: wpr-239308
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the outcomes of liver transplant recipients who received liver allografts from hepatitis B surface antigen (HBsAg)-positive donors.</p><p><b>METHODS</b>The medical records of 23 male patients (median age, 42.5 years; range 29-61) who received HBsAg-(+) liver allografts in our organ transplant center were retrospectively analyzed. All patients had confirmed diagnosis of end-stage liver disease (ESLD) secondary to hepatitis B virus (HBV) infection, including 13 HBsAg(+)/HBeAg(-)/HBcAb(+) cases and 10 HBsAg(+)/HBeAb(+)/HBcAb(+) cases. After transplantation, all patients were administered oral entecavir and intravenous anti-hepatitis B immunoglobulin (HBIG) (2000 IU/d during the first week), along with a steroid-free immune suppression regimen. HBV-related antigen and antibody and HBV DNA were detected on post-transplantation days 1, 7, 14, 21, and 30. The liver allografts were monitored by ultrasound imaging. After discharge, monthly follow-up recorded liver function, renal function, acute rejection, infections, vascular complications, biliary complications, HBV recurrence, cancer recurrence, and patient survival.</p><p><b>RESULTS</b>Two of the recipients died from severe perioperative pneumonia. The remaining 21 recipients were followed-up for 10 to 38 months, and all 21 patients remained HBsAg(+). One recipient developed biliary ischemia and required a second liver transplantation at five months after the primary transplantation. Three recipients (all primary) died from tumor recurrence at 9, 14, and 18 months post-transplantation, respectively. All other recipients survived and had acceptably low HBV DNA copy levels. Color Doppler imaging showed good graft function and normal texture. The patient and graft survival rates were 78.3% (18/23) and 73.9% (17/23), respectively. The recurrence rate of HBV infection was 100% (23/23). In surviving patients, no liver function abnormality, graft loss, or death was found to be related to the recurrence of HBV infection.</p><p><b>CONCLUSION</b>Liver transplantation using HBsAg(+) liver grafts was safe for patients with ESLD secondary to HBV infection.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Recurrence / General Surgery / Tissue Donors / Virology / Retrospective Studies / Liver Transplantation / Allergy and Immunology / End Stage Liver Disease / Hepatitis B Surface Antigens / Methods Type of study: Observational study Limits: Adult / Humans / Male Language: Chinese Journal: Chinese Journal of Hepatology Year: 2012 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Recurrence / General Surgery / Tissue Donors / Virology / Retrospective Studies / Liver Transplantation / Allergy and Immunology / End Stage Liver Disease / Hepatitis B Surface Antigens / Methods Type of study: Observational study Limits: Adult / Humans / Male Language: Chinese Journal: Chinese Journal of Hepatology Year: 2012 Type: Article